Compare Charles River Laboratories Intl. Inc (CRL) vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF (PDBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $226.38 (market cap $11.14B), while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $17.05. The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF nearer its low. Which is the better fit depends on your goals.
| CRL | PDBC | |
|---|---|---|
Market Cap | $11.14B | — |
Sector | Health | — |
52-Week High | $233.60 | $18.91 |
52-Week Low | $145.57 | $12.90 |
Enterprise Value | $14.00B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
PDBC trades at $16.90, up 2.8% today, with a bullish technical signal supported by moving averages and strong momentum indicators. The ETF has delivered significant returns, including 37% since March 2024, outperforming the S&P 500. Recent news highlights its role as a diversified commodity strategy without K-1 tax forms, attracting institutional interest despite variable dividend payouts tied to commodity prices.
The outlook remains positive due to ongoing commodity strength and geopolitical supply risks, but investors face volatility from fluctuating distributions and potential momentum shifts. Key risks include oil price sensitivity and roll costs, while institutional activity shows mixed signals with some reducing positions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF
The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →
